A new daily tablet has demonstrated superior weight loss and blood sugar control compared to oral semaglutide in a major clinical trial, marking a significant challenge to the injectable drugs that have dominated the weight loss market in recent years.
The compound, orforglipron, reduced average blood sugar levels by 1.71 to 1.91 percent over 52 weeks in patients with type 2 diabetes, outperforming oral semaglutide's 1.47 percent reduction. Participants taking orforglipron also shed between 6.1 and 8.2 kilograms, compared to 5.3 kilograms for those on semaglutide. The findings come from a phase 3 trial involving 1,698 adults across six countries.
The rise of injectable semaglutide under brand names Wegovy and Ozempic transformed obesity treatment by mimicking a natural gut hormone that signals fullness to the brain. Yet injections create real barriers for patients: needle anxiety, the burden of self-administration, and the need for cold storage throughout the supply chain, a particular constraint in developing nations. These limitations prompted pharmaceutical companies to pursue oral alternatives.
Oral semaglutide exists but carries significant drawbacks. It must be taken on an empty stomach with a 30-minute wait before eating or drinking. More problematically, only about 1 percent of the ingested dose enters the bloodstream, requiring expensive manufacturing and limiting its potency.
Orforglipron, developed by Eli Lilly, belongs to a new class called small-molecule drugs. Unlike peptide-based drugs such as semaglutide, small molecules are synthetic compounds simple enough to be absorbed through the intestinal wall without resembling the natural GLP-1 hormone structurally. This fundamental difference makes orforglipron cheaper and easier to manufacture while eliminating refrigeration requirements, a major advantage for global distribution.
The trial results suggest orforglipron could be a credible competitor to semaglutide's dominance. The weight loss observed in this study parallels what injectable GLP-1 drugs have achieved, though no direct head-to-head comparison has been conducted between the pill and injectables.
Yet a substantial hurdle emerged. Orforglipron triggered gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation in nearly 59 percent of participants, compared to 37 to 45 percent taking semaglutide. The reason likely stems from higher daily peak drug concentrations in the pill, causing greater temporary GI disruption. About 10 percent of orforglipron users discontinued treatment because of adverse effects, versus just 4 to 5 percent on semaglutide.
In a crowded marketplace where patients weigh efficacy against tolerability, this safety gap could prove decisive. Superior blood sugar control means little if half the patient population experiences intolerable side effects. The trial's data underscore that in oral weight loss drugs, keeping people on the medication may matter as much as how much weight they lose.
Orforglipron is still being tested in patients with obesity alone, outside the diabetes population. Those trials will help clarify whether the GI tolerability issues persist and whether market adoption can overcome the adherence challenges exposed by this latest evidence.
Author Jessica Williams: "Orforglipron has the manufacturing advantage and the efficacy edge, but that nausea problem is a real market killer if the drug can't be reformulated to smooth out those daily peaks."
Comments